Litigation Groups

Tenofovir

Aims to educate members and provide a forum to brainstorm ideas about the way to most effectively represent clients negatively impacted by tenofovir. The group provides member benefits such as access to pleadings, discovery, legal research, listserves, education programs, a medical literature database, and opportunities to share ideas in educational meetings.

Join Litigation Group

Tenofovir

Over a 14-year period, Gilead Sciences, Inc. ("Gilead") profited from exposing its patients to TDF-based medications by actively concealing and failing to bring to market safer, more effective TAF-based alternatives. Had Gilead acted reasonably under the circumstances in which it developed tenofovir as an antiretroviral treatment for HIV-1, it would have abandoned TDF in favor of TAF, thus reducing the risk of foreseeable and avoidable injuries like chronic kidney disease, renal failure, and bone mineral density disorders.

The Tenofovir Litigation Group aims to educate members and provide a forum to brainstorm ideas about how to most effectively represent clients negatively impacted by tenofovir. The Group provides member benefits such as access to pleadings, discovery, legal research, list servers, education programs, a medical literature database, and opportunities to share ideas in educational meetings.

The Tenofovir Litigation Group is sponsored by Epiq.

Join the Conversation

Litigation Group members, visit AAJ's Community Center to connect with your colleagues, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login